|Positive WB detected in||Daudi cells, Raji cells, Ramos cells|
|Positive IP detected in||Ramos cells|
|Positive IHC detected in||human lymphoma tissue, human tonsillitis tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||Ramos cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
The immunogen of 26709-1-AP is BSAP,PAX5 Fusion Protein expressed in E. coli.
|Host / Isotype||Rabbit / IgG|
|Immunogen||BSAP,PAX5 fusion protein Ag25147|
|Full Name||paired box 5|
|Calculated molecular weight||391 aa, 42 kDa|
|Observed molecular weight||42 kDa|
|GenBank accession number||BC156927|
|Gene ID (NCBI)||5079|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
PAX5, also named B-cell specific activator protein (BSAP), is a member of the highly conserved paired box (PAX)-domain family of transcription factors. PAX5 is essential in normal B-cell lymphopoiesis. It is expressed in pro-B, pre-B and mature B lymphocytes but not in plasma cells. PAX5 is a common target in leukemogenesis of B-ALL ( B-lineage acute lymphoblastic leukemia) along with CDKN2A. Owing to its frequent deletion in B-ALL, PAX5 could be used as one of the molecular markers in diagnosis and monitoring of the disease. This antibody is specific to PAX5. It will not cross react with other PAX members.
|Product Specific Protocols|
|WB protocol for BSAP,PAX5 antibody 26709-1-AP||Download protocol|
|IHC protocol for BSAP,PAX5 antibody 26709-1-AP||Download protocol|
|IP protocol for BSAP,PAX5 antibody 26709-1-AP||Download protocol|
|FC protocol for BSAP,PAX5 antibody 26709-1-AP||Download protocol|
|Click here to view our Standard Protocols|
J Cutan Pathol
Superficial sarcomas with CIC rearrangement are aggressive neoplasms: A series of eight cases.
Cancer Cell Int
Targeting Lymphotoxin Beta and Paired Box 5: a potential therapeutic strategy for soft tissue sarcoma metastasis.